Chronic GVHD (cGVHD) is a major complication of allogeneic hematopoietic SCT. Post transplant thrombocytopenia in patients with cGVHD has been associated with poor outcome and its etiology is unclear. We investigated whether thrombopoiesis, assessed via measurement of the absolute immature platelet number (AIPN) in the blood, is impaired in cGVHD, and whether the level of thrombopoiesis correlates with the severity and activity of cGVHD as assessed via the National Institutes of Health (NIH) organ scoring system. We used a cohort of 110 well-characterized cGVHD patients, including 83 (75%) with severe cGVHD per NIH global score. Higher AIPN was associated with active therapeutic intent (P ¼ 0.026), lower Karnofsky score (P ¼ 0.0013), worse joint/fascia cGVHD (P ¼ 0.0005) and worse skin cGVHD (P ¼ 0.0044). AIPN correlated with platelet counts and was not correlated with ANC, WBC, C-reactive protein (CRP), absolute lymphocyte count (ALC), albumin, total and average NIH scores, or number of prior systemic therapies. AIPN values for cGVHD patients substantially overlapped those of the normal population. Higher AIPN, as marker of active thrombopoiesisis, was associated with worse severity and activity of cGVHD, especially skin and joints/fascia manifestations. Among patients with stable moderate or severe cGVHD, there was no evidence of hypoproduction of platelets. Future studies should further investigate the role of thrombopoiesis in cGVHD.
INTRODUCTION
The etiology of thrombocytopenia in patients following transplantation, particularly in those with chronic GVHD (cGVHD), is likely multifactorial and is of unclear etiology. 1 Decreased production could theoretically result from insufficient engrafted hematopoietic stem cells because of a low transplanted dose or destruction via rejection or other hematopoietic stem cell damaging processes, marrow suppression from drugs or viral infection, or graft-versus-host attack on the marrow microenvironment, as recently demonstrated in a murine model. 2 Increased destruction could be related to consumption because of transplant-associated microangiopathy or to an auto-immune thrombocytopenic purpuralike syndrome. There is some evidence for both impaired thrombopoiesis and a shortened half-life of platelets in patients with GvHD. 3, 4 However, it is difficult in individual patients to assess the role of impaired thrombopoiesis versus platelet destruction in patients with thrombocytopenia, and study the impact of cGVHD on the BM, because assessment of megakaryocyte number on BM biopsy is only roughly quantitative and repeated sampling is not feasible, and there are few accurate or quantitative measures of ongoing platelet destruction. An understanding of the etiology of thrombocytopenia in these patients could have therapeutic relevance, as well as inherent biologic interest.
In 2006, Yamazaki et al. evaluated prolonged thrombocytopenia in allogeneic hematopoietic stem cell transplantation (alloHSCT) alloHSCT recipients using the glycocalicin index, TPO levels and anti-GPIIb-IIIanti-platelet Abs as measures designed to assess platelet turnover, platelet production and antiplatelet Ab responses, respectively. 3 They compared thrombocytopenic alloHSCT recipients with immune thrombocytopenic purpura and aplastic anemia patients. The glycocalicin index and TPO status in alloHSCT recipients with thrombocytopenia had a pattern similar to that seen in aplastic anemia, whereas glycocalicin index in alloHSCT recipients with thrombocytopenia was significantly lower than in patients with immune thrombocytopenic purpura, suggesting a major role for impaired thrombopoiesis in alloHSCT recipients. The patients in this study were diverse, analyzed early following transplantation and not fully characterized regarding cGVHD. Glycocalicin index as a measure of platelet destruction has low sensitivity and can give falsely elevated results in hypoplastic anemias, 4 circulating TPO levels have a complex relationship to thrombopoiesis and platelet destruction, 5 and the detection of specific antiplatelet Abs is challenging, not routinely available in most hospitals, and of unclear significance post transplantation.
As an alternative approach to assessing post transplant thrombopoiesis, we have focused on a simple peripheral blood test as a sensitive and practical measurement of ongoing thrombopoeisis. The Sysmex XE-2100 blood cell counter has been developed to measure the fraction of newly released immature platelets containing high amounts of cytoplasmic RNA in the peripheral blood, analogous to measurement of reticulocytes in the erythroid lineage. The absolute immature platelet number 1 Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA; (AIPN) has been used to predict marrow recovery after hematopoietic transplantation and to assess the level of thrombopoesis in patients with immune thrombocytopenic purpura. 6 In our own recent study, AIPN has been shown to correlate with ongoing megakaryocyte production of platelets, even in the setting of recent platelet transfusion. 6 In the current study, we asked whether thrombopoiesis as assessed via AIPN is impaired in patients with cGVHD, long-term following allo-SCT and to investigate any positive or negative correlations between AIPN and the severity and activity of cGVHD, as assessed via the National Institutes of Health (NIH) scoring system.
PATIENTS AND METHODS

Study design
This study describes patients with cGVHD evaluated at the NIH between May 2009 and September 2012. The NIH cGVHD program has established a multidisciplinary clinic and research network to study the pathogenesis and natural history of cGVHD, enrolling patients in the National Cancer Institute Institutional Review Board-approved natural history protocol NCT00092235 emphasizing cross-sectional data and specimen collection. Patients were evaluated using multiple disease scales and outcome measures, including the 2005 NIH Consensus Project cGVHD severity scores. Between May 2009 and September 2012, a total of 123 consecutive patients were enrolled, 13 patients were ineligible owing to no sample sent for AIPN. Therefore, 110 patients meeting the diagnostic criteria specified in the NIH cGVHD Consensus Project and with available AIPN data were included in this analysis (Table 1) . 7 All subjects signed National Cancer Institute Institutional Review Board-approved informed consent. In all, 48 of the 110 patients, enrolled between 2009 and 2010, were included in a prior analysis of inflammation and cGVHD, however, that study did not assess thrombopoiesis via measurement of AIPN in the patient cohort. 8 Patient-and transplant-related variables surveyed included recipient age, gender, time from transplant to analyzed visit, donor relationship (related or not), cord blood donor, TBI conditioning, cGVHD onset, GVHD classification at the time of analyzed visit, current systemic therapy for cGVHD, platelet count, AIPN, NIH global score, therapeutic intent, Karnofsky score, organ involvement (skin, eyes, oral, liver, gastrointestinal tract, lungs, joints/fascia, female genital), maximum score for an organ, intensity and type of immunosupression, and treatment received before registration date.
Disease was defined as 'active' if the practitioner decided to increase systemic therapy due to worsening disease, to substitute systemic therapy due to lack of response or withdraw systemic therapy due to lack of response. Disease was defined as 'non-active' if the practitioner decided to decrease systemic therapy because the cGVHD was improving, not to change current systemic therapy because cGVHD was stable or to alter systemic therapy only because of toxicity. 8 
AIPN
The AIPN was measured using a Sysmex XE-5000 automated hematology analyzer, with platelet gating accomplished using forward light scatter and identification of immature platelets achieved by staining with polymethine and oxazine fluorescent dyes (Sysmex America, Lincolnshire, IL, USA). 9 These fluorescent dyes penetrate cell membranes and bind to and fluorescently stain RNA, allowing separation of immature (RNA-rich) and mature platelets. Immature platelet fraction is expressed as a percentage, which represents the ratio of immature platelets to the total number of plateletes Â 100. AIPN was calculated by multiplying the platelet count by the immature platelet fraction and dividing by 100.
Statistical analysis
Comparisons between two groups of parameters were determined using a Wilcoxon rank sum test. Comparisons among three or more unordered categories were performed using a Kruskal-Wallis test. The association between AIPN and an ordered categorical parameter was determined by using the Jonckheere-Terpstra test for trend. 10 Correlation between AIPN and continuous parameters was determined using Spearman rank correlation. The magnitude of the correlation coefficient (r) is of much greater importance than the P-value, which is a test of whether r ¼ 0. Spearman correlations are interpreted as follows: |r|40.70 ¼ strong 19 (17) Abbreviations: cGVHD ¼ chronic GVHD; MDS ¼ myelodysplastic syndrome; PNH ¼ paroxysmal nocturnal hemoglobinuria. Active cGVHD by therapeutic intent at the time of the visit: (1) increase systemic therapy because cGVHD is worse; (2) substitute systemic therapy due to lack of response; and (3) withdraw systemic therapy due to lack of response. Non-active: (1) decrease systemic therapy because cGVHD is better; (2) not change current systemic therapy because cGVHD is stable; (3) alter systemic therapy owing to its toxicity. Other: either did not receive any immunosuppressive therapy or did not meet any of the criteria. None/mild, single-agent prednisone 0.5 mg/kg per day; moderate, singleagent prednisone 0.5 mg/kg/day and/or any single agent/modality; high, two or more agents/modalities ± prednisone 0.5 mg/kg/day. correlation; 0.5o|r|o0.7 ¼ moderately strong correlation; 0.3o|r|o0.5 ¼ weak to moderately strong correlation; |r|o0.3 ¼ weak correlation. Results are presented without any formal correction for multiple comparisons. However, in view of the number of statistical tests performed, Po0.005 is considered statistically significant, whereas 0.005oPo0.05 is considered a strong trend.
RESULTS
Patient population
The epidemiologic, disease and transplant characteristics of the population are given in Table 1 . The median age was 44 years (4-70 years). Median time from transplant to enrollment in the cGVHD study and assessment of clinical parameters and AIPN was 36 months (6-254).
cGVHD characteristics Overall, 83 of 110 patients (75%) were categorized as severe by the NIH global score (Table 2) ; with a median of five organs involved (1) (2) (3) (4) (5) (6) (7) (8) . In all, 77% were characterized with classic cGVHD and 20% were classified with overlap GVHD. The onset of cGVHD was progressive in 30%, de novo in 35% and quiescent in 35% ( Table 1 ). The most commonly involved organs were eyes (73%), skin (86%), lung (87%), joints and fascia (76%) and mouth (77%; Table 2 ). Global organ severity was driven primarily by skin disease (44%) and lung (44%; moderate plus severe), followed by joint/ fascia, eye and gastrointestinal tract involvement (Table 2 ).
AIPN
Higher AIPN was associated with active disease by therapeutic intent (P ¼ 0.026; Figure 1a ), lower Karnofsky (P ¼ 0.0013; Figure 1b ), worse NIH cGVHD joint/fascia (P ¼ 0.0005; Figure 2a ) and worse skin NIH cGVHD (P ¼ 0.0044; Figure 2b ), but not with NIH global score, type of transplant conditioning, donor relationship, cGVHD onset, cGVHD classification, genital NIH cGVHD, lung NIH cGVHD, liver NIH cGVHD, gastrointestinal tract NIH cGVHD, eye NIH cGVHD, mouth NIH cGVHD, maximal overall organ score, ANC, WBC, CRP, lactate dehydrogenase, lymphocyte count, albumin or number of prior systemic therapies. Patients requiring a higher intensity of immunosuppression were characterized by a higher AIPN (P ¼ 0.14), but without statistical significance, and specifically there was no association with patients being on or off calcineurin inhibitors, sirolimus or both, or with steroid dosing. AIPN was moderately correlated with platelet counts (r ¼ 0.42; Figure 3 ) and Karnofsky (r ¼ 0.37), but was not correlated with ANC, WBC, CRP, lymphocytes, albumin, total and average NIH scores, or number of prior systemic therapies.
AIPN showed no association in our cohort with NIH global score, type of transplant conditioning, donor relationship, cGVHD onset, cGVHD classification, genital NIH cGVHD, lung NIH cGVHD, liver NIH cGVHD, gastrointestinal tract NIH cGVHD, eye NIH cGVHD, mouth NIH cGVHD or maximum overall organ score.
We recently reported that in 107 normal volunteers, values of AIPN ranged from 2.4 to 20.7 with a mean of 6.0±2.7.
6 These values translate to an estimated 95% confidence interval of 0. 6-11.4 . In the present data, AIPN ranged from 1.4 to 34.7. The majority of our cGVHD cohort had an AIPN value within the normal range. Only 22 out 110 AIPN values were greater than 11.4, and only 3 exceeded 20.7. All three patients with elevated AIPN had severe cGVHD. Six patient's values were below 2.4 and three of these six patients with very low AIPN had less than 100 Â 10 9 /mL platelets.
DISCUSSION
Prior studies evaluating the relationship of cGVHD to thrombopoiesis have reported seemingly contradictory results. Higher platelet counts, presumably reflecting higher ongoing thrombopoiesis, correlated with more active and more severe cGVHD in our prior study. 8 This relationship was hypothesized to be related to ongoing inflammation and reactive thrombocytosis, potentially mediated by IL-6, which is a strong stimulator of platelet production. 12, 13 In addition, platelets may contribute to the pathogenesis of fibrosis via release of fibrogenic cytokines, and 
Abbreviations: cGVHD ¼ chronic GVHD; NIH ¼ National Institutes of Health. Mild cGVHD involves only one or two organs or sites with no clinically significant functional impairment (max score 1). Moderate involves at least one organ or site with clinically significant but no major disability (max score 2) or three or more organs or sites with no clinically significant functional impairment (max score 1). A lung score of 1 is also moderate cGVHD. Severe cGVHD indicates major disability caused by cGVHD (score 3). A lung score of 2 or 3 is also classified as severe cGVHD.
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Thrombopoiesis in cGVHD T Bat et al in that study, higher platelet counts were associated with more severe skin and joint/fascia cGVHD. Some reports have recognized thrombocytopenia at the time of cGVHD diagnosis as a poor prognostic factor for survival in cGVHD. 1, [14] [15] [16] [17] [18] In our current study of a large outpatient cohort of cGVHD patients, there was no evidence of absolute hypoproduction of platelets from the marrow, as the majority of patients had values for immature platelet levels within the normal range. All of our analyses linked a higher AIPN to worse cGVHD, as evidenced by significant correlations of AIPN with skin or joint/fascia scores, performance status, active therapy and a trend toward a correlation with higher intensity of immunosupression. These data do not provide evidence for a general graft-versus-marrow microenvironmental process in cGVHD impairing platelet production. In fact, only 16 patients, 13% of this population, had a below normal platelet counts and even fewer (n ¼ 3) had a platelet counts less than 100 000/mL and a low AIPN. So only in this subgroup is there evidence for platelet hypoproduction, potentially caused by a graft-versus-niche effect.
Our data instead support the hypothesis that ongoing inflammation in cGVHD stimulates increased thrombopoiesis in the most severe patients, most likely via higher levels of thrombopoietic cytokines. In this scenario, higher platelet production may be an acute phase reactant and a biomarker of cGVHD-associated inflammation, resulting from proinflammatory cytokines such as IL-6, IFN and IL-17 directly and indirectly stimulating thrombopoiesis. 8, 19, 20 The other possibility is that increased thrombopoiesis has an actual pathophysiologic role in the process of fibrogenesis in cGVHD, given that platelets and megakaryocytes release cytokines such as platelet-derived growth factor and transforming growth factor that stimulate fibrosis. 21, 22 This hypothesis needs to be tested in further studies and may have potentially important implications in devising future treatment strategies, including anti-inflammatory and cytokinespecific drugs for some of the most devastating and disabling symptoms of cGVHD. 8, 12, 13 It is possible that treatment with Thrombopoiesis in cGVHD T Bat et al agents that increase platelet production to a supraphysiologic level, such as thrombopoietic agonists, might worsen the fibrotic complications of cGVHD. How can we reconcile our finding that increased thrombopoiesis is associated with worse cGVHD with studies reporting that thrombocytopenia is associated with poorer outcomes in cGVHD? [14] [15] [16] [17] [18] It is important to note that these seminal studies examined thrombocytopenia as a prognostic factor only at the initial onset or diagnosis of cGVHD, usually within 1 year of transplantation, and did not study platelet counts specifically in association with organ-specific cGVHD manifestations or later in the course of cGVHD. As low platelet counts after allogeneic HSCT are not uncommon and are associated with worse survival, even without cGVHD, 23 it remains unsettled if a low platelet count at the onset of cGVHD is a specific process with poor prognosis, or is simply a manifestation of complex factors following allogeneic HSCT, some linked to acute GVHD, including ongoing infection, marrow suppressive drugs, endothelial damage, inflammation and autoimmunity. 8 Perhaps, patients with early onset of severe cGVHD have enhanced platelet destruction but are unable to appropriately compensate by increasing marrow production due to concurrent drug therapies, infection or simply incomplete recovery of marrow stem cell reserve early post transplantation. In contrast, our study included cGVHD outpatients a median of 3 years following transplantation, and enrolled very few patients in the first year post transplant. In our cohort, it is also relevant to stress that we may not have captured patients with early onset thrombocytopenia and severe cGVHD, as these patients may not have survived long enough to enroll in our long-term crosssectional natural history study.
There are some limitations of this study; this cohort did not include many patients with thrombocytopenia: only a few patients under 100 000 or even under 150 000/mL, so the question still remains if the marrow in those patients with very low platelets and cGVHD has lost the ability to make platelets, at least at a level sufficient to keep up with increased destruction. This study includes referral patients who are primarily late in the course of cGVHD with a particularly high prevalence of severe but stable cGVHD, especially skin and lung, and may not be representative of patient cohorts followed at transplant centers or earlier following transplantation. This study is by design a cross-sectional analysis of outpatients, which permits enrollment of a broad spectrum of the patients with the most severe forms of cGVHD but without intercurrent infectious complications or other acute confounding factors. Our observed association of higher AIPN and platelet counts with cGVHD activity and severity according to the NIH criteria should be explored in further studies focusing on longitudinal observation of patient cohorts after allogeneic HSCT. Future studies should also investigate any mechanistic connection between thrombopoiesis and cGVHD.
